Abstract
Severe sepsis is associated with a high mortality rate despite implementation of guidelinerecommendations. Thymosin alpha 1 (Ta1) has been used to treat severe sepsis as a promising beneficial immunomodulatory drug, but its mechanism remains unclear.
Highlights
Severe sepsis is associated with a high mortality rate despite implementation of guidelinerecommendations
There was no statistical significance between 28 day mortality rate in the control group and that of thymosin group(35.7% vs 23.1%, P=0.310)
TLR2, TLR4 and MyD88 mRNA expressions in the thymosin group were respectively increased on enrollment day, day 3 and day 7, this increasing trend was not found in the control group
Summary
Introduction Severe sepsis is associated with a high mortality rate despite implementation of guidelinerecommendations. Thymosin alpha 1 (Ta1) has been used to treat severe sepsis as a promising beneficial immunomodulatory drug, but its mechanism remains unclear.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
